[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Anthrax - Pipeline Insight, 2021

May 2021 | 60 pages | ID: A67BECA46A6EN
DelveInsight

US$ 1,500.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
This report can be delivered to the clients within 48 Hours

DelveInsight’s, “Anthrax - Pipeline Insight, 2021,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Anthrax pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
  • Global coverage
Anthrax Understanding

Anthrax: Overview

Anthrax is a serious infectious disease caused by gram-positive, rod-shaped bacteria known as Bacillus anthracis. Anthrax can be found naturally in soil and commonly affects domestic and wild animals around the world. Although it is rare in the United States, people can get sick with anthrax if they come in contact with infected animals or contaminated animal products. Anthrax can cause severe illness in both humans and animals.

'Anthrax - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Anthrax pipeline landscape is provided which includes the disease overview and Anthrax treatment guidelines. The assessment part of the report embraces, in depth Anthrax commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Anthrax collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights
  • The companies and academics are working to assess challenges and seek opportunities that could influence Anthrax R&D. The therapies under development are focused on novel approaches to treat/improve Anthrax.
Anthrax Emerging Drugs Chapters

This segment of the Anthrax report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Anthrax Emerging Drugs
  • AV 7909: Emergent BioSolutions
The vaccine candidate AV7909 is being developed for post-exposure prophylaxis of disease resulting from suspected or confirmed Bacillus anthracis exposure, in conjunction with the recommended course of antimicrobial therapy. AV7909 is comprised of Anthrax Vaccine Adsorbed (AVA) in combination with an adjuvant. Several Phase 1 and Phase 2 clinical studies have investigated the safety, efficacy, and stability profile of AV7909. The lot consistency, safety, and immunogenicity of AV7909 are currently being evaluated in a Phase 3 trial.
  • BW 1010: BlueWillow Biologics
BW-1010 is the company’s next-generation intranasal anthrax vaccine candidate. The vaccine is currently under phase 1 of clinical trials.

Further product details are provided in the report

Anthrax: Therapeutic Assessment

This segment of the report provides insights about the different Anthrax drugs segregated based on following parameters that define the scope of the report, such as:
  • Major Players in Anthrax
There are approx. 10+ key companies which are developing the therapies for Anthrax. The companies which have their Anthrax drug candidates in the most advanced stage, i.e. phase III include, Emergent BioSolutions.
  • Phases
DelveInsight’s report covers around 10+ products under different phases of clinical development like
  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration
Anthrax pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
  • Oral
  • Parenteral
  • intravitreal
  • Subretinal
  • Topical.
  • Molecule Type
Products have been categorized under various Molecule types such as
  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Anthrax: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Anthrax therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Anthrax drugs.

Anthrax Report Insights
  • Anthrax Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs
Anthrax Report Assessment
  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs
Key Questions

Current Treatment Scenario and Emerging Therapies:
  • How many companies are developing Anthrax drugs?
  • How many Anthrax drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Anthrax?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Anthrax therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Anthrax and their status?
  • What are the key designations that have been granted to the emerging drugs?
Key Players
  • Emergent BioSolutions
  • BlueWillow Biologics
  • Planet Biotechnology
  • Altimmune
  • GC Pharma
  • Crestone Inc
  • Greffex
  • Hawaii Biotech
  • Integrated BioTherapeutics
  • Q BioMed
  • VLP Biotech
  • Porton Biopharma
  • Aphios
  • DEINOVE
  • ENESI Pharma
  • Paratek Pharmaceuticals
  • Fab’entech
  • SporeGen
Key Products
  • AV 7909
  • BW 1010
  • PBI 220
  • NasoShield
  • GC-1109
  • Research programme: DNA vaccines
  • Ba-ISTAb
  • MAN 04
  • DNV3837
  • Nuzyra
Introduction
Executive Summary
Anthrax: Overview
  Causes
  Mechanism of Action
  Signs and Symptoms
  Diagnosis
  Disease Management
Pipeline Therapeutics
  Comparative Analysis
Therapeutic Assessment
  Assessment by Product Type
  Assessment by Stage and Product Type
  Assessment by Route of Administration
  Assessment by Stage and Route of Administration
  Assessment by Molecule Type
  Assessment by Stage and Molecule Type
Anthrax – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
  Anthrax companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Anthrax Collaboration Deals
  Company-Company Collaborations (Licensing / Partnering) Analysis
  Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
  Comparative Analysis
AV 7909: Emergent BioSolutions
  Product Description
  Research and Development
  Product Development Activities
Drug profiles in the detailed report
Early Stage Products (Phase I)
  Comparative Analysis
BW 1010: BlueWillow Biologics
  Product Description
  Research and Development
  Product Development Activities
Drug profiles in the detailed report
Inactive Products
  Comparative Analysis
Anthrax Key Companies
Anthrax Key Products
Anthrax- Unmet Needs
Anthrax- Market Drivers and Barriers
Anthrax- Future Perspectives and Conclusion
Anthrax Analyst Views
Anthrax Key Companies
Appendix

LIST OF TABLES

Table 1 Total Products for Anthrax
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products

LIST OF FIGURES

Figure 1 Total Products for Anthrax
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products


More Publications